AKT1 and hepatocellular carcinoma: Overexpression of SLC25A5 could both strengthen resistance to tyrosine kinase inhibitors in lung cancer [22] and reverse sorafenib resistance [23] via the PI3K/AKT pathway in hepatocellular carcinoma [24].